Q2 FY2026 · ended Jun 30, 2026 · Revenue $12.08M · Filed Sep 8, 2026
Apnimed, Inc. (APMD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $12.1 million and net income of $125.9 million. As of Jun 30, 2026 it held $172.8 million in cash and investments and $41.0 million in total debt.
Revenue
$12.08M
Net income
$125.94M
Operating cash flow
$-37.92M
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
41.63M
Net cash
$131.79M
Q2 FY2026
Operating margin
-96.9%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1745648
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Revenue | $12.1M |
| Operating income | -$11.7M |
| Net income | $125.9M |
| Operating cash flow | -$37.9M |
| Total assets | $195.5M |
| Total liabilities | $125.7M |
| Stockholders' equity | -$176.2M |
| Cash and investments | $172.8M |
| Total debt | $41.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 8, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 3, 2026 | Aug 3, 2026 |
All 55 Apnimed, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.